Flavone Acetic Acid and Interleukin-2 in Melanoma Treatment
Author Information
Author(s): S.M. O'Reilly, G.J.S. Rustin, K. Farmer, M. Burke, S. Hill, J. Denekamp
Primary Institution: Charing Cross Hospital and Mount Vernon Hospital, UK
Hypothesis
Does the combination of flavone acetic acid (FAA) and recombinant interleukin-2 (rIL-2) improve clinical outcomes in patients with advanced malignant melanoma?
Conclusion
The combination of FAA and rIL-2 resulted in a 14% overall response rate in patients with advanced melanoma, but no significant increase in tumor necrosis was observed.
Supporting Evidence
- One complete response and two partial responses were observed among the 21 assessable patients.
- Severe hypotension was noted in a significant number of patients after treatment.
- No increase in tumor necrosis was observed in any of the biopsies taken after therapy.
Takeaway
Doctors tested a new treatment for skin cancer using two drugs together, but it only helped a few people and didn't work like it did in mice.
Methodology
23 patients with metastatic melanoma received FAA and rIL-2 in a clinical trial, with assessments of response and toxicity.
Limitations
The study had a small sample size and a low response rate, and the lack of significant tumor necrosis raises questions about the treatment's effectiveness.
Participant Demographics
Patients had a mean age of 55, with a range of 21 to 74 years; 35% had poor performance status.
Want to read the original?
Access the complete publication on the publisher's website